Home | Patients | Newsroom
Newsroom
January 2022
AI harnessed for early identification of cardiovascular problems
Financial Times features Caristo co-founders Charalambos Antoniades and Cheerag Shirodaria, as they discuss how CaRi-Heart® analysis could help lift a huge financial burden from healthcare systems.
December 2021
AI To Improve Evaluation Of Diabetes Using Routine CT
Industrial News features Caristo’s research project, in collaboration with University of Oxford, that focuses on identifying people who maybe at risk of developing diabetes
December 2021
Our research highlights of 2021
From AI technology that can predict heart attacks to a potential new drug for incurable vascular dementia, the BHF has had a great year of scientific discoveries, each bringing us one step closer to making heart and circulatory disease a thing of the past.
December 2021
The Hottest Startups in Oxford
Caristo Diagnostics featured by The Wire among Oxford’s most promising startups
October 2021
CT Coronary Perivascular Fat Assessment Can Stratify Cardiac Risk Associated With High-Risk Plaques
This article in Diagnostic And Interventional Cardiology (DAIC) provides a nice summary of the data presented at last ESC.
September 2021
Artificial intelligence for heart attack prediction
Artificial intelligence (AI) can help identify people at high risk of a fatal heart attack years before it strikes – thanks to new research that we have funded.
August 2021
Two New AI assessments Offered in Welsh hospital
St Joseph’s Hospital, in partnership with Heart & Lung Imaging (H&L), has become the first hospital in Wales to offer two artificial intelligence (AI)-enabled imaging assessments, which can identify a range of respiratory and cardiac conditions, potentially in their earliest stages.
June 2021
Caristo recipient of an NHS AI Award Phase 3 project
The AI Award is making £140 million available over four years to accelerate the most promising AI technologies for health and social care. There have been two rounds of competition since its launch in September 2020.
June 2021
£36 million boost for AI technologies to revolutionise NHS care
Thousands of patients and NHS staff will benefit from dozens of new pioneering projects awarded a share of £36 million to test state-of-the-art AI technology. The projects will help the NHS to transform the quality of care and the speed of diagnoses for conditions such as lung cancer.
June 2021
Artificial intelligence that predicts heart attacks in use in hospitals
CaRi-Heart takes a normal CT scan, analyses it using AI technology and develops a more precise picture of conditions in a heart and arteries. The Sunday Telegraph
June 2021
Artificial intelligence for heart attack prediction
"Artificial intelligence (AI) can help identify people at high risk of a fatal heart attack years before it strikes – thanks to new research that we have funded." The British Heart Foundation highlights one of its research successes.
March 2021
Risk screening in cardiovascular disease: the role of CT coronary angiography in asymptomatic patients, why wait?
In this editorial of the British Cardiovascular Society, Dr. John Graby gives an excellent overview on the role of CCTA in assessing cardiovascular risk, highlighting the important role of FAI.
March 2021
Meet the founders
Cheerag Shirodaria and Charalambos Antoniades were recently interviewed by OSI (Oxford Sciences Innovation), one of the early investors of Caristo Diagnostics.
March 2021
Coverage of the BHF Press release on CaRi-Heart® receiving CE Mark
The announcement from the British Heart Foundation was featured as an exclusive article in the 28th of March edition of the Sunday Times.
March 2021
Caristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advance
Caristo Diagnostics, an Oxford-based health-tech company, is delighted to announce that its first product, CaRi-Heart®, has received a CE mark under the new European Medical Device Regulations (MDR). CaRi-Heart® will fundamentally disrupt the approach to diagnosis and treatment of coronary artery disease, by predicting heart attacks years before they happen with the measurement of coronary inflammation from a routine coronary CT scan. Caristo’s mission is to transform health outcomes through clinical and scientific innovation, using scientific breakthroughs made by Cardiologists at the University of Oxford...
February 2021
Índice de atenuação de gordura (FAI): uma mudança de paradigma na cardiologia
Dr. Fabiano M. Serfaty interviews Dr. Cheerag Shirodaria, physician associated with the discovery of the Fat Attenuation Index (FAI). Medscape Brazil (article in Portuguese).
Prof Antoniades presents new AI-powered Imaging biomarker at European Society of Cardiology
Sep 03 Our Founder and Chief Scientific Officer Professor Charalambos Antoniades today presented a late-breaking paper at the ESC Congress in Paris, with a simultaneous publication in the European Heart Journal. It describes novel ground-breaking AI-powered biomarkers that enhance and add on to our existing FAI technology. It not only looks at inflammation signatures in the fat, but also adverse fibrotic and microvascular remodelling. The result is a marked increase in the power of cardiovascular risk prediction, well above and beyond the current start of the art. Caristo is proud that its proprietary CaRi-HEART algorithms were used in part of the research!

Click here to read more.
Press Coverage of Prof. Antoniades new AI-based CVD risk prediction
Our Founder and CSO Professor Charalambos Antoniades has generated considerable media interest with his recent simultaneous ESC Congress presentation and European Heart Journal paper. In this work he and his team applied state-of-the-art machine learning techniques to the extraction of information from routine coronary CT scans. Some of the work used Caristo’s proprietary CaRi-HEART algorithms! Here are selected articles from the lay press:

The Telegraph
The Sun
The Times
Daily Mail
Independent.ie
Gulf News
Oxford researchers show FAI is superior to other CT measurements in CVD risk prediction
At the European Society of Cardiology Congress in Paris this week, the research team behind Caristo Diagnostics – led by Professor Charalambos Antoniades – presented a paper in the Young Investigator Awards session. Congratulations to the author, Dr Evangelos Oikonomou, who went on to win the prestigious Young Investigator Award for this work!
The research looked at existing CT angiography based risk measurements, based on plaque features, and compared them to FAI™. The results showed conclusively that the predictive power of FAI™ leaves the more traditional markers behind.

Click here to read more.
The CRISP-CT study
THE LANCET: Coronary artery inflammation inhibits adipogenesis in adjacent perivascular fat. A novel imaging biomarker—the perivascular fat attenuation index (FAI™)—captures coronary inflammation by mapping spatial changes of perivascular fat attenuation on coronary computed tomography angiography (CTA). However, the ability of the perivascular FAI™ to predict clinical outcomes is unknown.

Click here to read more.
New ways of reading scans can predict heart attack risk, research find
THE GUARDIAN: Researchers says colour of fat surrounding a heart's arteries can predict risk, meaning expensive drugs can be given to those most likely to benefit. Heart attacks may soon be easier to predict thanks to a method of reading routine heart scans that can pinpoint those most at risk, research suggests. Every year, roughly 750,000 Americans have a heart attack and around half die from it, often before reaching hospital. In the UK, someone has a heart attack every seven minutes. Doctors hope to identify the highest risk patients so they can be given preventative treatment and advised to adopt lifestyle changes.

Click here to read more.
Peri-coronary adipose tissue density is associated with 18F-Sodium Fluoride coronary uptake in stable patients with high-risk plaques
The validity of our novel biomarker, the Fat Attenuation Index (FAI™), has recently been confirmed in a study by Kwiecinski et al, published in the Journal of the American College of Cardiology: Cardiovascular Imaging. This international study showed that changes in perivascular adipose tissue density assessed using CCTA were strongly correlated with coronary inflammation assessed using 18F-sodium fluoride PET imaging.

This is exciting confirmation of our methodology, and two of Caristo’s founders, Professor Charalambos Antoniades and Dr. Cheerag Shirodaria have written an editorial to accompany this important publication. We are pleased to see independent validation of our work from a leading global CCTA research group. FAI™ remains poised to become a game-changing refinement of cardiovascular risk prediction, and we look forward to future studies further establishing FAI™ as an essential tool for the future of cardiovascular disease management.
Treatment with biology therapy in psoriasis is associated with reduction in coronary artery inflammation
AMERICAN COLLEGE OF CARDIOLOGY CONFERENCE: At the American College of Cardiology Conference, an exciting abstract from Scientists at the US National Institute of Health (NIH) was presented showing a statistically-significant reduction in FAI™ associated with anti-inflammatory treatment for psoriasis. Psoriasis is commonly associated with increased risk of vascular inflammation and CV events. This landmark finding that highlights the dynamic nature of FAI™ means it is poised to become a standard measure of treatment response in CVD.

Click here to read more.
Winner of 2019 Eurominnies
UNIVERSITY OF EDINBURGH: Congratulations to the SCOT-HEART investigators, who have been awarded a 2019 EuroMinnie Award for Scientific Paper of the Year. This is important recognition of the leading role CT angiography is poised to play in coming years as a front line diagnostic test for coronary heart disease.

New tools such as Caristo’s Fat Attenuation Index will enable doctors to extract unprecedented levels of information from a simple scan, enabling a truly personalized determination of cardiovascular disease risk.

Click here to read more.
Noninvasive detection of perivascular inflammation by Coronary Computed Tomography in the CRISP-CT study and its implications for residual cardiovascular risk
EUROPEAN SOCIETY OF CARDIOLOGY: Coronary computed tomography angiography (CTA) is an established and highly sensitive non-invasive technique to detect obstructive and non-obstructive coronary artery disease (CAD). However, it has not been well-studied as a technique to detect inflammatory changes (or its impact on future coronary events) in the surrounding fatty tissue. Recently, a new index, fat attenuation index (FAI™), has been developed to detect and quantify changes in perivascular fat resulting from ongoing inflammation, using clinically acquired coronary CTA. […] The perivascular FAI™ potentially identifies higher-risk patients who may have highly inflamed and potentially unstable atherosclerotic plaques. Routine coronary CT angiography could help potentially identify the residual inflammatory risk that is captured by the perivascular FAI™. These are patients who might not get recognized early and the use of this new biomarker could potentially help institute intensive preventative strategies.

Click here to read more.
Noninvasive coronary imaging with Cardiac Computed Tomography and Cardiovascular Magnetic Resonance
UPTODATE: We are pleased to report that Caristo’s new imaging biomarker, the Perivascular Fat Attenuation Index (FAI™), has been featured in UpToDate’s latest chapter on Noninvasive Coronary Imaging. UpToDate is the leading evidence-based, physician-authored clinical decision support resource that is used by over 1.3 million clinicians in 187 countries.

The article referenced our original Science Translational Medicine paper from 2017 as well as the landmark CRISP-CT trial, published in the Lancet in August 2018. The authors noted that, "In patients with suspected angina, coronary inflammation, estimated on CT with attenuation measurements of the perivascular fat, may be a predictor of poor patient outcome. In a retrospective analysis of two prospectively acquired CCTA databases with 1872 and 2040 participants in the derivation and validation cohorts, respectively, a pericoronary fat attenuation index (FAI™) of ≥-70.1 Hounsfield units, measured around the right coronary artery, was independently associated with all-cause mortality (hazard ratio [HR] 1.5, 95% CI 1.2–1.9 in the derivation cohort; 1.8, 95% CI 1.5–2.3 in the validation cohort) and cardiac mortality (HR 2.2, 95% CI 1.3–3.5 in the derivation cohort; 2.1, 1.5–2.8 in the validation cohort)."

Caristo looks forward to working with clinicians to bring this new technology to the forefront of cardiovascular medicine very soon.

Click here to read more.
Oxford secured £17.5 Million to lead national AI Healthcare programmes
Caristo Diagnostics is proud to have been part of the bid which secured funding for NCIMI in Oxford.

University of Oxford: Innovate UK and industry are to invest more than £17.5 million in the University of Oxford to develop artificial intelligence (AI) healthcare applications to benefit patients. […] Oxford is to be home to one of the five new technology centres across the country, and is also a collaborator in two of the other centres, with local activities integrated within the Big Data Institute. The University of Oxford led centre is the National Consortium of Intelligent Medical Imaging (NCIMI), in which UK Research and Innovation is investing £10 million. NCIMI will also benefit from a further £5 million of funding provided from its commercial partners. The consortium includes 15 NHS hospitals, industry (including GE Healthcare and Alliance Medical), charities, and patient support groups to develop new artificial intelligence tools to help speed up diagnosis of cancer, heart disease, genetic disorders and other conditions.

Click here to read more.
Vulnerable plaque: are targeted therapies within reach?
MEDSCAPE: Rupture of unstable nonobstructive plaque is the underlying cause of most acute coronary syndromes.[1,2] However, imaging tests to identify high-risk plaque features such as thin-cap fibroatheroma (TCFA) or spotty calcification are not practical for everyday use and have had mixed success for predicting future events. […] Two recent studies aim to bring vulnerable plaque identification into the cath lab routine, and trials of targeted therapies are ongoing. At the 2018 European Society of Cardiology, the CRISP-CT study used the perivascular fat attenuation index (FAI™)—a measure of coronary inflammation—to predict events in nearly 4000 patients undergoing CT angiography. Perivascular FAI™ represents the first noninvasive assessment of coronary inflammation; high values were associated with increased cardiac mortality (cut-off ⋝–70.1 Hounsfield units). Stephan Achenbach, MD (Friedrich-Alexander-University, Erlangen, Bavaria, Germany), who was involved in CRISP-CT, views it as a change in thinking: "The old theory is that the fat influences the plaque. Now the Oxford researchers have turned this around, it’s the plaque influencing the fat," he said in an interview...

Click here to read more.
Researchers test new techniques to rule out and predict heart attacks
JAMA: A new protocol to rule out myocardial infarctions (MIs), or heart attacks, in emergency departments using a recently approved high-sensitivity troponin t test was found to be safe and accurate in a study published in Circulation. Most US hospitals use an older troponin assay that’s less sensitive and precise than the new high-sensitivity assay, according to lead study author Rebecca Vigen, MD, a cardiologist at the University of Texas Southwestern Medical Center in Dallas. Her team developed a novel protocol for using the new test based on published studies and European guidelines, which endorse it for ruling out MI.

Click here to read more.